Professional
Added to YB: 2026-05-22
Pitch date: 2026-05-20
RXRX [neutral]
Recursion Pharmaceuticals, Inc.
+6.51%
current return
Author Info
Pernas Research is a former CIO of a $3.5B fund that now share actionable stock research. Sign up for the newsletter.
Company Info
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
Market Cap
$1.6B
Pitch Price
$2.92
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.06
P/E
-2.53
EV/Sales
14.89
Sector
Biotechnology
Category
growth
Pernas Research Passes On: Recursion Pharmaceuticals
RXRX (pass): AI-native drug discovery platform w/ massive proprietary multimodal biological dataset from automated wet labs. Trades 15x EV/Sales. Uncertain if current data scale sufficient for clinical outcomes. Exscientia acquisition added integration complexity. Still a 'show me' story pending trial validation vs hype. Too speculative.
Read full article (1 min)